Gregory Hayes bought $1.0M of BDX
director at BECTON DICKINSON & CO. 5,250 shares at an average of $191.57, traded Aug 11, 2025, filed Aug 11, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.0M at market
- +10Relative to holdingsHoldings up 660%
- +4Price context22% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000010795-25-000081, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | POpen-market purchase Common Stock | +5,250 | $191.57 | $1.0M | 6,046 | Aug 11, 2025 |
Related signals
Other insiders at BECTON DICKINSON & CO and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP, Chief Revenue Officer | $14k 76 shares | -0% | |
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $10k 58 shares | -1% | |
| 26Weak | BDXsell BECTON DICKINSON & CO | Claire Fraser director | $172k 917 shares | -4% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $11k 57 shares | -1% | |
| 34Weak | BECTON DICKINSON & CO | Claire Fraser director | $166k 863 shares | -4% | |
| 0Weak | BECTON DICKINSON & CO | Michael David Garrison EVP & President, Medical | $214k 1,185 shares | -20% | |
| 12Weak | BECTON DICKINSON & CO | David Shan EVP and Chief ISC Officer | $200k 1,166 shares | -20% | |
| 5Weak | BECTON DICKINSON & CO | Michael David Garrison EVP & President, Medical | $94k 479 shares | -9% | |
| 5Weak | BECTON DICKINSON & CO | Richard Byrd EVP & President Interventional | $106k 459 shares | -6% | |
| 17Weak | BECTON DICKINSON & CO | Richard Byrd EVP & President Interventional | $436k 1,940 shares | -21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.